en Pediatrics Pediatrics Review Article Review Article <p><span style="font-size:14px;"><span style="font-family:times new roman;"><span style="color:#0000FF;"><strong><em>Background: </em></strong></span>Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine.<br> <span style="color:#0000FF;"><strong><em>Methods: </em></strong></span>This review article was designed based on PRISMA guidelines. To review the literature, two researchers studied national and international databases including Iranmedex, Magiran, Medlib, SID, Scopus, PubMed, Science Direct, Web of Science and Google Scholar without time limit until May 2017. Cochran&#39;s Q test and I² index were used to assess the heterogeneity of the studies. The data were analyzed using Comprehensive Meta-Analysis software version 2 and p<0.05 was considered significant.<br> <span style="color:#0000FF;"><strong><em>Results:</em></strong> </span>A total of 17 articles involving 1,835 Iranian thalassemia major patients treated with deferoxamine were included in the meta-analysis. The overall prevalence of hearing loss was estimated 27.3% (95% confidence intervals (CI): 19-37.6). The prevalence of sensorineural, conductive and mixed hearing loss was estimated 10.6% (95% CI: 5.7-18.8), 14.6% (95% CI: 10.5-20.6) and 9.1% (95% CI: 5.6-14.6), respectively. No significant differences were noted regarding the relationship hearing loss and mean serum ferritin (P=0.29) and average daily deferoxamine (P=0.30). Meta-regression model showed an increased significance in the prevalence of hearing loss based on the year of studies (p<0.0001).<br> <span style="color:#0000FF;"><strong><em>Conclusions:</em></strong> </span>There is a high prevalence of hearing loss in Iranian thalassemia major patients treated with deferoxamine. Therefore, periodic hearing assessments and regular check-ups after the initiation of chelation therapy are necessary.</span></span></p> Hearing Loss, Thalassemia Major, Deferoxamine, Systematic Review, Meta-analysis, Iran 239 249 http://caspjim.com/browse.php?a_code=A-10-509-2&slc_lang=en&sid=1 Gholamreza Badfar gh_badfar@yahoo.com 10031947532846009972 10031947532846009972 No Department of Pediatrics, Behbahan School of Medicine, Ahvaz jundishapour university of Medical science, Behbahan, Iran Akram Mansouri akram.mansouri2@gmail.com 10031947532846009973 10031947532846009973 No School of Nursing and Midwifery, Ahvaz jundishapour university of Medical science, Ahvaz, Iran Masoumeh Shohani shohani-m@medilam.ac.ir 10031947532846009974 10031947532846009974 No Faculty of Nursing and Midwifery, Ilam University of Medical Sciences, Ilam, Iran. Hamid Karimi 10031947532846009975 10031947532846009975 No Department of Endocrinology, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran Zahra Khalighi 10031947532846009976 10031947532846009976 No Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, Iran Shoboo Rahmati shoboorahmati2014@gmail.com 10031947532846009977 10031947532846009977 No Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran Ali Delpisheh alidelpisheh@yahoo.com 10031947532846009978 10031947532846009978 No Department of Clinical Epidemiology, Ilam University of Medical Sciences, Ilam, Iran Yousef Veisani yousefveisani@yahoo.com 10031947532846009979 10031947532846009979 No Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran Ali Soleymani ali.soleymani1360@yahoo.com 10031947532846009980 10031947532846009980 No Dezful University of Medical Sciences, Dezful, Iran Milad Azami milad98azami@gmail.com 10031947532846009981 10031947532846009981 Yes Student Research Committee, Dezful University of Medical Sciences , Dezful, Iran